NCT02324972View on ClinicalTrials.gov

Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
Atopic Dermatitis
Interventions
DRUG

AQX-1125

Synthetic SHIP1 activator

DRUG

Placebo

Trial Locations (1)

Unknown

AQX-Innovaderm site, Montreal

Sponsors

Collaborators (1)

Innovaderm Research Inc.
All Listed Sponsors
collaborator

Innovaderm Research Inc.

OTHER

lead

Aquinox Pharmaceuticals (Canada) Inc.

INDUSTRY